Free tool
FAERS Monitor: Poteligeo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761051 or its brand name (Poteligeo, Mogamulizumab-Kpkc). Reports on generic versions are filed under their own applications.
Reports
1,361
Serious
819
60% of reports
Hospitalization
240
Death reported
198
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash193
- disease progression123
- drug eruption81
- pruritus68
- infusion related reaction59
- death55
- pyrexia52
- fatigue49
- inappropriate schedule of product administration42
- chills41
- drug ineffective37
- erythema36
- lymphopenia34
- nausea34
- off label use33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 22 |
| 2019 | 210 |
| 2020 | 179 |
| 2021 | 223 |
| 2022 | 227 |
| 2023 | 109 |
| 2024 | 134 |
| 2025 | 125 |
| 2026 | 120 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,798 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug eruptionSignal | 81 | 71.0 | 57.4 | 5,496 |
| lymphopeniaSignal | 34 | 37.2 | 26.7 | 1,161 |
| disease progressionSignal | 123 | 16.1 | 13.6 | 1,732 |
| infusion related reactionSignal | 59 | 13.8 | 10.7 | 687 |
| rashSignal | 193 | 6.8 | 6.0 | 977 |
| chillsSignal | 41 | 5.4 | 4.0 | 144 |
| inappropriate schedule of product administrationSignal | 42 | 3.6 | 2.7 | 77 |
| pruritusSignal | 68 | 2.7 | 2.2 | 74 |
| erythemaSignal | 36 | 2.7 | 2.0 | 37 |
| pyrexiaSignal | 52 | 2.3 | 1.8 | 38 |
| death | 55 | 1.0 | 0.8 | 0 |
| fatigue | 49 | 1.0 | 0.7 | 0 |
| nausea | 34 | 0.7 | 0.5 | 6 |
| off label use | 33 | 0.6 | 0.4 | 10 |
| drug ineffective | 37 | 0.4 | 0.3 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.